Early-stage and mid-stage biotech raises using AI

The landscape of early-stage and mid-stage biotech is experiencing a notable surge in funding, particularly for startups leveraging artificial intelligence (AI) to revolutionize therapeutics, microbiome research, and platform technologies. This trend underscores a sustained venture capital appetite for computational biotech innovations that aim to accelerate discovery, improve precision, and expand the scope of biotech applications.

AI-Enabled Therapeutic Discovery and Platform Development

Several startups are harnessing AI to target previously undruggable conditions. For example, Antiverse, a UK-based biotech, recently secured £7 million (£9.3 million) in Series A funding led by Soulmates Ventures. Antiverse is developing novel antibodies for diseases that have eluded traditional drug discovery methods, leveraging AI to streamline the identification and optimization process. This highlights a broader shift towards AI-driven platforms that can rapidly generate therapeutic candidates with higher success probabilities.

Similarly, Salma Health, a digital health company focusing on brain health, launched with a substantial $80 million Series A round. Their approach integrates AI to better understand and treat neurological and psychiatric conditions, reflecting the increasing integration of computational methods in mental health and neurotherapeutics.

Microbiome Modeling and Programmable Microbes

The microbiome remains a fertile area for innovative biotech solutions. Outpost Bio, a London- and Boston-based startup, raised $3.5 million to develop AI-driven models of human microbiology. Their goal is to make the complex ecosystem of bacteria, fungi, and other microbes more computationally accessible, enabling precise manipulation and understanding of the microbiome’s role in health and disease.

Complementing this, Paris-based baCta raised €7 million to develop microorganisms as programmable molecular factories for industrial ingredients. By utilizing AI to engineer microbes with specific functions, baCta aims to create scalable, sustainable biomanufacturing processes, exemplifying how AI can accelerate microbial engineering for both health and industrial applications.

Innovations in Neuromuscular and Neurotechnology

Advancements are also occurring at the intersection of neurotechnology and biomedicine. Noxon, a Munich-based MedTech startup, closed seed funding to develop digital interfaces for neuromuscular care. Their non-invasive neuro- and muscle interface technologies aim to improve treatment outcomes for neuromuscular disorders, illustrating how AI and digital interfaces are transforming patient care.

Significance and Future Outlook

The influx of funding into these startups underscores continued strong VC interest in computational biotech platforms. Whether through AI-enabled drug discovery, microbiome modeling, programmable microbes, or neurointerfaces, investors recognize the transformative potential of AI to accelerate development timelines, reduce costs, and unlock new therapeutic avenues.

This trend signals a maturing ecosystem where platform plays and therapeutic innovations driven by AI are becoming central to biotech investment strategies. As these startups advance, we can expect to see more sophisticated applications of AI that not only enhance our understanding of complex biological systems but also lead to novel treatments across a spectrum of diseases.